EWING, N.J. -- Shares of Antares Pharma Inc. climbed Wednesday after the drug developer said U.S. regulators will review its application for the potential rheumatoid arthritis and psoriasis treatment Otrexup.
The Ewing, N.J., company said the Food and Drug Administration intends to complete its review and make a decision on whether to approve the treatment by Oct. 14.
Antares makes self-injectable drugs. Otrexup combines the company's Medi-Jet drug delivery system, which allows patients to inject a drug, and methotrexate, a commonly prescribed rheumatoid arthritis treatment.
Antares shares climbed 4.6 percent, or 16 cents, to $3.52 in midday trading, while broader trading indexes rose less than 1 percent.
0 comments:
Post a Comment